CRYOPORT, INC. (NASDAQ: CYRX)
FIRST QUARTER 2026 IN REVIEW
May 4, 2026

Important information

This document provides a review of Cryoport, Inc.'s operational performance during the first quarter (Q1) of 2026, covering the three-month period ended March 31, 2026, and a general business outlook, supplementing our Q1 2026 earnings release. It is designed to be read by interested parties before the regularly scheduled quarterly conference call, which, for this quarter, is scheduled for 5:00 p.m. ET on Monday, May 4, 2026. Therefore, the conference call will be in the format of a questions and answers session and will address any questions the investment community has regarding the Company's results.

Conference Call Information

Date:	May 4, 2026
Time:	5:00 p.m. ET
Dial-in numbers:	1-800-717-1738 (U.S.), 1-646-307-1865 (International)
Confirmation code:	Request the "Cryoport Call" or Conference ID: 1191652
Live webcast:	'Investor Relations' section at www.cryoportinc.com or click here. Please allow 10 minutes prior to the call to visit this site to download and install any necessary audio software.

Questions and answers will be recorded and available approximately three hours after completion of the live event on the Investor Relations section of the Company's website at www.cryoportinc.com for a limited time. To access the replay of the questions and answers, please follow this link. A dial-in replay of the call will also be available to those interested, until May 11, 2026. To access the replay, dial 1-844-512-2921 (United States) or 1-412-317-6671 (International) and enter replay entry code: 1191652#.

FIRST QUARTER 2026 FINANCIAL RESULTS OVERVIEW

Business description	***Cryoport, Inc. (Nasdaq: CYRX)*** *is a leading global provider of integrated temperature-controlled supply chain solutions for the life sciences, with a strategic focus on supporting the development and commercialization of cell and gene therapies. Leveraging advanced technologies, proprietary logistics systems, and industry-leading expertise, Cryoport delivers mission-critical services that ensure the safe, compliant, and efficient transport, storage, and monitoring of temperature-sensitive biopharmaceutical materials.*
Client Examples	• **Biopharma/Pharma:** *Bristol Myers Squibb, Gilead, Vertex Pharma, Crispr Therapeutics, Lonza, J&J, Thermo Fisher Scientific, Iovance* • **Animal Health:** *Zoetis, Genus PLC, Boehringer Ingelheim, Elanco* • **Reproductive Medicine:** *TMRW/Reprotech, Inception, CCRM, IVI RMA, Pinnacle Fertility, Virtus Health, Carrot Fertility, Monash Fertility*
Revenue	Q1 2026: $47.8 million (+16.5% YoY)
Number of Global Clinical Trials Currently Supported	766 clinical trials - 91 in Phase 3
2026 Full Year Revenue Guidance	$192.0 - $196.0 million (Updated)
Cash, Cash Equivalents & Short-Term Investments	$403.6 million
CEO	Jerrell Shelton

A Great Start to 2026

Our first quarter results continue to demonstrate our leadership position as Cryoport delivered revenue of $47.8 million, up 16% year-over-year, reflecting a continuation of our momentum over the past several quarters. Revenue in support of commercial Cell and Gene Therapies (CGT) grew 26% to $9.1 million, while clinical trial support revenue grew 18% to $12.9 million. We continue to support one of the industry's broadest CGT pipelines, and our leadership across both clinical and commercial programs positions us well for sustainable growth.



Our Life Sciences Services segment delivered another strong quarter, with revenue increasing 18% year-over-year, including 21% growth in BioStorage/BioServices. This performance reflects increasing adoption of our full services portfolio in conjunction with the increasing scope and complexity of the Cell Therapy programs we support and underscores the critical role we play in supporting our clients with our integrated, temperature-controlled supply chain services. BioLogistics Solutions revenue increased 17% year-over-year in Q1 2026, driven by increasing customer activity, continued commercial product maturation, and clinical advancement within the CGT market.



Our Life Sciences Products segment also performed well, generating 15% revenue growth, driven by global demand for MVE Biological Solutions' cryogenic systems. MVE continues to innovate and further solidify its position as the global leader in high-quality cryogenic systems.



Execution and Operational Discipline

Growth across both of our reporting segments, Life Sciences Services and Life Sciences Products, combined with solid gross margins and continued operational discipline, drove a **$2.2 million year-over-year improvement in adjusted EBITDA from continuing operations**, advancing us meaningfully along our "pathway to profitability."

We exited Q1 2026 with $403.6 million in cash, cash equivalents, and short-term investments. With our strong balance sheet and emphasis on higher margin services, we have ample resources to execute on our strategic growth initiatives and are well positioned for further growth in 2026 and beyond.



Expanding CGT Market with Increasing Funding

The global CGT market was estimated at $8.94 billion in 2025 and is projected to reach approximately $47.18 billion by 2035, expanding at a CAGR of 18.1% from 2026 to 2035. Cell and Gene therapies have continued to enter and move through the clinical pipeline, which should result in growing revenues from commercially approved therapies

The CGT market's growth continues to be driven by the increased prevalence of chronic diseases fueling patient demand, continued U.S. Food and Drug Administration (FDA) approvals, a robust clinical pipeline, increased R&D and advancements in medical technology and gene-editing tools.



Cryoport continues to maintain its competitive differentiation as the only pure-play, end-to-end temperature-controlled supply-chain platform and supporting the largest portfolio of clinical and commercial Cell & Gene therapies worldwide.

Total biopharma funding has remained strong with April 2026 funding up ~422% year-over-year and up ~72% month-over-month. April's funding was driven by 13 public transactions greater than $200 million and five public transactions that were over $100 million.



Biopharma Equity Investments ($B)



Source: FactSet, UBS; Note: Includes Venture, IPOs, and equity follow-on; Data as of 4/30/2026; Percentage represents year-over-year change.

As of March 31, 2026, Cryoport supported 21 commercial therapies and a record total of 766 global clinical trials, a net increase of 55 clinical trials compared with March 31, 2025. Of these trials, 91 were in Phase 3 and 357 were in Phase 2. In total, Cryoport supported approximately 70% of global CGT trials. Approximately 60% of the global clinical trials supported by Cryoport were autologous cell therapies, 29% were allogeneic cell therapies, 6% were gene therapies, and 5% were vaccines, biologics and other trials. Building on this market-leading position, we believe we are well positioned to continue to drive strong growth in both the near and the long term.

Patients First: Supporting the Therapies of Tomorrow

Clinical Trials Supported, by Trial Phase



21 Commercial Therapies Supported

CGT Industry Market Share[1]

Source: Company materials cross-referenced to clinical trial information publicly available

Forecasted BLA / MAA Filings & Patient Population Growth

Currently forecasts up to 14 possible BLA / MAA filings and 9 approvals in 2026, with the majority being for new therapies

- Industry experts anticipate 30 - 50 additional CGT approvals by 2030
- The patient population for CGTs is projected to grow significantly as more treatments are approved
- The Company continues to introduce capabilities to its existing clients and adds new clients to its global network
- Remains focused on scaling its services to meet the needs of the patient population growth

By geographic region, as of March 31, 2026, Cryoport supported 569 trials in the Americas, 143 in EMEA, and 54 in APAC (Asia-Pacific). This compares to 544 in the Americas, 118 in EMEA, and 49 in APAC as of March 31, 2025.

Cryoport Supported Clinical Trials by Phase

Clinical Trials	March 31,		
	2024	2025	2026
Phase 1	286	304	318
Phase 2	312	328	357
Phase 3	77	79	91
Total	**675**	**711**	**766**

Cryoport Supported Clinical Trials by Region

Clinical Trials	March 31,		
	2024	2025	2026
Americas	518	544	569
EMEA	112	118	143
APAC	45	49	54
Total	**675**	**711**	**766**

In Q1 2026, four (4) Biologics License Applications (BLA) / Marketing Authorization Applications (MAA) filings occurred. Looking ahead, for the balance of 2026, we anticipate ten (10) application filings and eight (8) additional new therapy approvals.

During the first quarter, Cryoport's customer, Rocket Pharmaceuticals, received accelerated approval from the FDA for their gene therapy KRESLADI™ for the treatment of pediatric patients with severe leukocyte adhesion deficiency-I (LAD-I). Severe LAD-I is an ultra-rare, life-threatening pediatric genetic immunodeficiency characterized by recurrent infections and high early-childhood mortality. This approval represents a breakthrough treatment as this is the first FDA-approved gene therapy to treat this disease.

MVE – Leading the Pack Through Innovation

MVE's New Fusion® 800 Series

MVE Biological Solutions' (MVE) continues to cement its position as the global leader in the production of high-quality cryogenic systems by bringing innovative products and services to the market. During the first quarter, MVE introduced its new Fusion® 800 Series, a breakthrough self-sustaining cryogenic freezer that eliminates the need for a continuous liquid nitrogen supply feed. These freezers deliver exceptional reliability, safety, and sustainability in a compact footprint designed for space-constrained environments where a readily available source of liquid nitrogen is not available.

Upcoming Growth Catalysts

Looking ahead, we see multiple growth catalysts extending beyond 2026 that we believe will further strengthen our long-term growth trajectory. These include the planned launch of BioServices operations at our Global Supply Chain Center in Paris, France in the third quarter of

this year, which is expected to significantly enhance our service capabilities and geographic reach across Europe.

Global Supply Chain Centers

In addition, we are progressing toward the planned opening of our new Global Supply Chain Center in Santa Ana, California, planned for the fourth quarter of 2026. This Global Supply Chain Center will expand our services available across the Western United States while consolidating three existing facilities into a more efficient and scalable operation.

Together, these strategic investments expand our global footprint in key geographies, enhance operational efficiencies, and further strengthen our ability to support the advancement and commercialization of life-saving therapies globally.

Other strategic initiatives we have made progress with include IntegriCell®, our cryopreservation services devised to address a critical element in maximizing the supply chain for the development and commercialization of cell-based therapies through high quality, standardized, cryopreserved starting materials. During the first quarter we reached a 'milestone moment' as our IntegriCell team cryopreserved and shipped its first clinical trial patient materials from both our Houston, Texas and Liege, Belgium facilities for two separate clients. This achievement highlights IntegriCell's progress as it continues to develop and moves a step further toward being a meaningful contributor to Cryoport's future revenue and profitability.

In parallel, we continued to advance our digital and information strategy, including the deployment of digitization and generative AI to begin assisting in providing information to support complex internal workflows and improve our effectiveness and efficiency in day-to-day operations. Our focus is currently on enabling employees to use secure, enterprise-approved generative AI tools to automate repetitive tasks, analyze data in real time, manage risk, and accelerate decision-making and execution. We are already seeing tangible benefits and believe AI will play an increasingly important role in our future.

Raised Outlook For 2026

In closing, we had a great start to 2026 marked by 16% revenue growth year-over-year and strong double-digit growth across both of our core reporting business segments. Our Life Sciences Services segment grew 18% year-over-year, driven by 21% growth in BioStorage/BioServices revenue, a 26% increase in revenue from Commercial Cell & Gene Therapies support, and clinical trial related revenue growth of 18%. And, at the same time, Life Sciences Products segment revenue grew 15%, driven by global demand for MVE's cryogenic systems. This topline growth was accompanied by solid gross margins and continued operational discipline, which resulted in a $2.2 million year-over-year improvement in adjusted EBITDA from continuing operations.

Reflecting our strong performance for the first quarter and our increased visibility into the remainder of the year, we are raising our full-year 2026 revenue guidance to $192.0 million to $196.0 million. We will continue to review our guidance on a quarterly basis and make any further adjustments as warranted. We also believe that, based on our progress year-to-date, we will achieve positive adjusted EBITDA in the second half of this year. Our entire team continues to be excited about the opportunities we see ahead of us and we look forward to keeping you updated on our progress as we continue to build on our current momentum.

The Company's 2026 guidance is dependent on its current business and expectations, which may be impacted by, among other things, factors that are outside of our control, such as national economic factors, the global macroeconomic and geopolitical environment, supply chain constraints, inflationary pressures, any U.S. federal government shutdown, tariffs and other trade restrictions and/or the effects of foreign currency fluctuations, as well as the other factors described in the Company's filings with the Securities and Exchange Commission ("SEC"), including in the "Risk Factors" section of its most recently filed periodic reports on Form 10-K and Form 10-Q, as well as in its subsequent filings with the SEC.

First Quarter 2026 Financial Results

Please refer to the Q1 2026 Earnings Release published on our website www.cryoportinc.com under *Investor Relations*.

Upcoming Financial Conferences

Cryoport's management team frequently participates in financial conferences and other industry events, including virtual conferences, to ensure it is in regular communication with the investment community. Upcoming Company participations are shown in the following table:

Host	Conference	Date	Location
Craig-Hallum	Institutional Investor Conference	May 27-28, 2026	Minneapolis
Jefferies	Healthcare Conference	June 2-4, 2026	New York
Wells Fargo	Healthcare Conference	September 8-10, 2026	Boston
Jefferies	Healthcare Services Conference	September 14-15, 2026	Nashville
Morgan Stanley	Global Healthcare Conference	September 14-16, 2026	New York

Forward-Looking Statements

Statements in this document which are not purely historical, including statements regarding the Company's intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, those related to the Company's industry, business, long-term growth prospects, plans, strategies, acquisitions, future financial results and financial condition, such as the Company's outlook and guidance for full-year 2026 revenue and the related assumptions and factors expected to drive revenue, projected growth trends in the markets in which the Company operates, the Company's plans and expectations regarding the launch of new products and services, such as the expected timing and benefits of such products and services launches, the Company's expectations about future benefits of its acquisitions, and anticipated regulatory filings, approvals, label/geographic expansions or moves to earlier lines of treatment approved with respect to the products of the Company's clients. Forward-looking statements also include those related to the Company's expectations about future benefits relating to the CRYOPDP divestiture and strategic partnership with DHL (collectively, the "DHL Transaction"), the Company's plans regarding its Global Supply Chain Centers, including expected timing of future openings, the Company's plans and expectations relating to its strategic pivot to expand its global partnerships, and the Company's expectation of revenue contribution from IntegriCell's cryopreservation service centers throughout 2026. It is important to note that the Company's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, risks and uncertainties associated with the effects of changing economic and geopolitical conditions, supply chain constraints, inflationary pressures, tariffs and other trade restrictions, foreign currency fluctuations, trends in the products markets, any U.S federal government shutdown, variations in the Company's cash flow, market acceptance risks, and technical development risks. Additional risks and uncertainties relating to the DHL Transaction include, but are not limited to, the risk that any disruption resulting from the DHL Transaction may adversely affect our businesses and business relationships, including with employees and suppliers. The Company's business could be affected by other factors discussed in the Company's SEC reports, including in the "Risk Factors" section of its most recently filed periodic reports on Form 10-K and Form 10-Q, as well as in its subsequent filings with the SEC. The forward-looking statements contained in this press release speak only as of the date hereof and the Company cautions investors not to place undue reliance on these forward-looking statements. Except as required by law, the Company disclaims any obligation and does not undertake to update or revise any forward-looking statements in this document.

About Cryoport, Inc.

Cryoport, Inc. (Nasdaq: CYRX), is a leading global provider of integrated, temperature-controlled supply chain solutions for the life sciences, with an emphasis on regenerative medicine. We support biopharmaceutical companies, contract manufacturers (CDMOs), contract research organizations (CROs), developers, and researchers with a comprehensive suite of services and products designed to minimize risk and maximize reliability across the temperature-controlled supply chain for the life sciences. Our integrated supply chain platform includes the Cryoportal® Logistics Management Platform, advanced temperature-controlled packaging, informatics, specialized biologistics, biostorage, bioservices, cryopreservation services, and cryogenic systems, which in varying combinations deliver end-to-end solutions that meet the rigorous demands of the life sciences. With innovation, regulatory compliance, and agility at our core, we are ***"Enabling the Future of Medicine™."***

Headquartered in Nashville, Tennessee, our company maintains a strong global presence with operations across the Americas, EMEA, and APAC.

For more information, visit www.cryoportinc.com or follow via LinkedIn at https://www.linkedin.com/company/cryoportinc or @cryoport on X, formerly known as Twitter at www.x.com/cryoport for live updates.